1 / 32

Cooling in MI

Cooling in MI. Myocardial Protection and Preservation. "Cell protection is the new challenge for patient management in coronary care units, the catheterization laboratory, and the operating room, broadening our management strategies for acute coronary syndromes"

teagan-obrien
Télécharger la présentation

Cooling in MI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cooling in MI

  2. Myocardial Protection and Preservation "Cell protection is the new challenge for patient management in coronary care units, the catheterization laboratory, and the operating room, broadening our management strategies for acute coronary syndromes" "Cell protection may be the next breakthrough in clinical cardiology" Pierre Theroux (Circulation 2000:101: 2874-2876)

  3. The Continuum of Carefor the Ischemic Myocardium • Reperfusion is not enough • Protecting and preserving the myocardium is the next evolution of care for these patients Reperfusion (PCI, Lytics, Anti- thrombotic) Regeneration (EGF, Angiogenesis) Myocardial Protection & Preservation (Endovascular Temperature Therapy) Mechanical Prevention/ Support (Filters, Traps, LVAD) PRESENT FUTURE

  4. Metabolic Support &Myocardial Preservation • There is considerable research that demonstrates that cooling to mildly hypothermic levels (32-33°C)*: • Reduces infarct size • Decreases myocardial and whole body metabolism and 02 demand on ischemic myocardium • Enhances ATP retention and prolongs tissue viability • Reduces inflammatory response • Decreases platelet aggregation • Increases myocardial efficiency * Am J Physiol Heart Circ. Physiol 2002; 285: H1584-91, Basic Res Cardiol 1998; 93: 372-83, Am J Physiol Heart Circ. Physiol 1996; 270: H1189-99, Am J Physiol Heart Circ. Physiol 1998; 274: H786-793, Neurosurgery 1996; 39: 1200-5, Thromb Haemost 1994; 71: 633-40, Basic Res Cardiol 2001; 86: 195-205

  5. Endovascular Temperature Therapy in MI Goal: Cell protection and preservation in ischemic tissues • No current therapies preserve cells. Focus has been on reperfusion and mechanical barriers, i.e. filters • Cell death continues during and after reperfusion is established

  6. Endovascular TemperatureTherapy System TM • Closed loop, 10 Fr central venous heat exchange catheter 0ptimized for rapid cooling and warming • Easy-to-use heat exchange cassette facilitates rapid initiation of therapy and patient transfer • Easy-to-use second generation controller efficiently delivers thermal energy • U.S. FDA 510(k) clearance in June, 2002 for use in cardiac surgery to achieve and/or maintain normothermia

  7. Cooling in MIPre-Clinical Evidence

  8. 100 80 60 40 20 0 34 35 36 37 38 39 40 Pre-Clinical ResearchTemperature & Infarct Size* y = 20x - 720 r = 0.84, p < 0.001 Infarct Size (% of Area at Risk) Body Core Temperature (º C) * Am J Physiol Heart Circ. Physiol 1996; 270: H1189-99

  9. Pre-Clinical ResearchEndovascular Cooling in MI* • Study Design • 22 human sized swine with LAD ligation to simulate MI • Randomized to endovascular cooling (34° C) or normothermia (38° C) utilizing the Reprieve™ System • Measured hemodynamics, area at risk and infarct size • Heart rate, Systolic BP, Stroke Volume and Cardiac Output • Blue dye to identify area at risk • TTC and sestamibi TC99m to measure infarct size * Am J Physiol Heart Circ. Physiol 2002; 285: H1584-91

  10. Pre-Clinical ResearchEndovascular Cooling in MI* Re-Occlusion Blue Dye TTC & Sestamibi Occlusion Reperfusion Cooling Ligation Reperfusion 1 hour 3 hours HR, SBP, SV, CO * Am J Physiol Heart Circ. Physiol 2002; 285: H1584-91

  11. Pre-Clinical Research -Endovascular Cooling in MI*Normothermic (Red) vs. Cooled (Blue) Temperature PlotsNote: Temperature is not dependent on open artery. * Am J Physiol Heart Circ. Physiol 2002; 285: H1584-91

  12. Pre-Clinical ResearchEndovascular Cooling in MI* • Results • Cooling reduced infarct size by 80% • Major protection occurred at target temp of 34°C • No increase in arrhythmia • Cardiac output maintained during ischemia and reperfusion • Decrease in heart rate • Increase in stroke volume * Am J Physiol Heart Circ. Physiol 2002; 285: H1584-91

  13. Pre-Clinical Research - Endovascular Cooling in MI*Area at Risk & Infarct Size Sestamibi Normothermia Hypothermia AAR/TTC White area = infarcted tissue * Am J Physiol Heart Circ. Physiol 2002; 285: H1584-91

  14. Pre-Clinical Research - Endovascular Cooling in MI*Area at Risk & Infarct Size P < .000001 P = 0.6 * Am J Physiol Heart Circ. Physiol 2002; 285: H1584-91

  15. Cooling in MIThe COOL MI™ Feasibility Trial

  16. Systemic Hypothermia as an Adjunct to Primary Angioplasty for Acute Myocardial Infarction* Results of a Safety and Feasibility Study SR Dixon, MBChB; RJ Whitbourn, MBBS, FRACP; Michael W. Dae, MD, FACC; Eberhard Grube, MD; Warren Sherman, MD, FACC; Gary L. Schaer, MD, FACC; Stephen Jenkins, MD, FACC; Donald S. Baim, MD, FACC; Raymond J. Gibbons, MD, FACC; Richard E. Kuntz, MD, FACC; Jeffrey J. Popma, MD, FACC; Thanh T. Nguyen, DO; William W. O'Neill, MD, FACC * JACC 2002; 40: 1928-34

  17. Clinical Sites • St Vincent’s Hospital Melbourne, Australia • William Beaumont Hospital Royal Oak, MI • Rush-Presbyterian-St.Luke’s Medical Center Chicago, IL • Alton-Oschner Medical Center New Orleans, LA • Beth Israel Medical Center New York, NY • Brigham & Women's Hospital Boston, MA • Stanford University Medical Center Palo Alto, CA • Heart Center Siegburg Siegburg, Germany * JACC 2002; 40: 1928-34

  18. Study Objective • To determine: • Feasibility and safety of endovascular cooling in patients with acute MI undergoing primary PCI • Feasibility of shivering management • Preliminary efficacy assessment • Infarct size at 30-days with 99mTc-sestamibi SPECT imaging * JACC 2002; 40: 1928-34

  19. Study Design 42 Patients Key Inclusion: Acute MI < 6 Hours, Anterior and Large Inferior MI’s Key Exclusion: Prior MI < 1 month, Cardiogenic Shock, Hypersensitivity to cold or anti-shivering agents PCI + Endovascular Cooling PCI Alone Endpoints: In-hospital & 30-day MACE, SPECT Infarct size at 30 days * JACC 2002; 40: 1928-34

  20. COOL MI Feasibility Trial Endovascular Cooling Protocol • Cooling initiated before PCI (in ER or cath lab) • Target temperature 33o C • Cooling maintained for 3-hours after PCI • Re-warming over 1-2 hours • Core temperature monitored with naso-esophageal probe • Skin warming (forced air blanket), oral buspirone and, intravenous meperidine used to prevent shivering * JACC 2002; 40: 1928-34

  21. Shivering Management Optimal Endovascular Therapy is dependent on successfully managing three interdependent factors • Adequate dosing with Buspirone and Meperidine to reduce shivering threshold • Use of warm air blanket to “fool” skin receptors • Rate of cooling the core and temperature maintentance Skin Sensor Management Drug-Brain Threshold Endovascular Temperature * JACC 2002; 40: 1928-34

  22. Patient Demographics* * JACC 2002; 40: 1928-34 *p=0.02

  23. Procedural Data* * JACC 2002; 40: 1928-34

  24. Core Temperature During Cooling* * JACC 2002; 40: 1928-34

  25. 160 140 120 100 80 60 40 20 0 Hemodynamics During Cooling* Aos Aod HR 180 0 30 60 90 120 150 180 210 240 TIME (Mins) * JACC 2002; 40: 1928-34

  26. In-hospital Adverse Events* * JACC 2002; 40: 1928-34

  27. Final Infarct Size at 30-days(Tc-99m SPECT)* TIMI 0-1 TIMI 2-3 Median Group Infarct Size Assigned infarct size for patients who died * JACC 2002; 40: 1928-34

  28. COOL MI Pivotal Trial

  29. COOL MI Pivotal TrialSummary • Multi-center, prospective randomized study consisting of 400 patients at up to 25 sites • Designed to evaluate the safety and effectiveness of endovascular cooling as an adjunctive therapy to PCI in patients with AMI when compared to PCI alone • Adult patients with chest pain >30 min but <6 hrs, diagnosed with anterior or large inferior infarcts and eligible for primary PCI

  30. Study Design 400 Patients Key Inclusion: Acute MI >30 min and< 6 Hours, Anterior and Large Inferior MIs Key Exclusion: Prior MI < 1 month, Cardiogenic Shock, Hypersensitivity to cold or anti-shivering agents PCI + Endovascular Cooling PCI Alone Primary Effectiveness Endpoint: SPECT Infarct size at 30 days Primary Safety Endpoint: MACE, all-cause mortality and adverse events Secondary Endpoints: LVEF (using SPECT at 30 days), Cardiac Enzymes, Myocardial Blush, ST-segment resolution and hematological responses

  31. COOL MI Pivotal Trial Study Management • Principal Investigator: William O’Neill, MD, Director Division of Cardiology, William Beaumont Hospital • Data Management & Analysis: Harvard Clinical Research Institute (HCRI) – Richard Kuntz, MD • Nuclear Imaging Core Laboratory: Mayo Clinic – Raymond Gibbons, MD • Angiographic Core/Blush Laboratory: HCRI – Jeffrey Popma, MD • ECG Core Laboratory: HCRI – Peter Zimetbaum, MD

  32. COOL MI Pivotal Trial Summary • Initial clinical results with endovascular temperature therapy in AMI support the pre-clinical findings of decreased infarct size. • Pivotal trial initiated in late 2001, enrollment nearly complete as of 1/1/2003 • Results to be presented in 2003

More Related